This document outlines details of PBS-subsidised azacitidine, decitabine+cedazuridine and lenalidomide for patients with myelodysplastic syndrome (MDS).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure of how to action an application.
Myelodysplastic syndrome quick reference
|
Restrictions |
Authority level and section |
PA assessment |
Processing system |
Prescriber type |
Prescriber self-serve |
|
Initial
or
First Continuing
PB012 form |
Written
Electronic
S100:
lenalidomide
|
No |
OPA |
Not specified |
Yes |
|
Initial |
Telephone
Electronic
S100:
azacitidine
S85:
decitabine+cedazuridine (general listing)
|
No |
OPA |
Not specified |
Yes |
|
Subsequent
Continuing
|
Telephone
Electronic
S100:
lenalidomide
|
No |
OPA |
Not specified |
Yes |
|
Continuing
|
Telephone
Electronic
S100:
azacitidine
S85:
decitabine+cedazuridine (general listing)
|
No |
OPA |
Not specified |
Yes |
Expand all